Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06368414
Other study ID # KCMLWP-2021-04
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date September 1, 2024
Est. completion date August 31, 2028

Study information

Verified date April 2024
Source Korean Society of Hematology
Contact Hawk Kim
Phone 82-10-8533-8019
Email ksh.cml.wp@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI


Description:

We expect that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 69
Est. completion date August 31, 2028
Est. primary completion date August 31, 2028
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. 19 year or older 2. CP-CML patients who are taking current TKIs (imatinib, nilotinib or dasatinib) for 5 years or more 3. Patients who have failed maintaining MR3.0 after 1 or more cessation trial of TKIs. 4. Patients who regained MR3.0 or deeper molecular response by TKIs retrial after TKI cessation failure at the time of screening 5. Taking TKIs over 12 weeks for the retrial of TKIs after TKI cessation failure 6. Patients who agree with stopping asciminib and TKIs after maintaining 23 year-duration of MR4.5 7. Adequate end organ function as defined by: - Total bilirubin (TBL) < 3 x upper limit of normal (ULN); patients with Gilbert's syndrome may only be included if TBL = 3.0 x ULN or direct bilirubin = 1.5 x ULN - Creatinine clearance (ClCr) = 30 mL/min as calculated using Cockcroft-Gault formula - Serum lipase = 1.5 x ULN. For serum lipase > ULN - = 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis 8. Patients who can sign the informed consent of their own free will Exclusion Criteria: 1. Patients who experienced grade 3 or higher adverse events with TKIs (imatinib, dasatinib, and nilotinib). 2. Patients who are receiving any other investigational agents. 3. Patients who currently have uncontrolled infections 4. Patients who previously received Chimeric antigen receptor T-cell (CAR-T cell) therapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) or biologic therapy. 5. Patients with clinically significant cardiovascular disease or gastrointestinal dysfunction. 6. Patients who have a history of thromboembolic episodes within 3 months prior to the study enrollment. 7. Patients with active hepatitis B or C with uncontrolled disease activity. 8. Patients who have active malignancies requiring treatment other than CML. 9. Patients with any severe and/or uncontrolled medical conditions or other conditions that could adversely impact on patients' ability to participate in the study. 10. Patients with psychiatric illness/social situations that would limit compliance with study requirements. 11. Pregnant women are excluded from this study Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with asciminib and TKIs, breastfeeding should be discontinued if the mother is treated with asciminib and TKIs.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Asciminib
that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Korean Society of Hematology

References & Publications (1)

Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006 Aug 15;145(4):247-54. doi: 10.7326/0003-4819-145-4-200608150-00004. Erratum In: Ann Intern Med. 2008 Oct 7;149(7):519. Ann Intern Med. 2021 Apr;174(4):584. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary MR3.0 or less by 1 year To evaluate the cumulative incidence of sustained MR3.0 or less by 1 year of cessation of TKI and asciminib by 1 year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06409936 - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Phase 2
Terminated NCT04006847 - Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Phase 1/Phase 2
Active, not recruiting NCT04126681 - A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase Phase 2
Not yet recruiting NCT05543161 - "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"
Recruiting NCT05638763 - Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia Phase 2
Recruiting NCT03610971 - Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors Phase 2
Completed NCT03332511 - Efficacy and Safety of Nilotinib in CML-CP Phase 4
Active, not recruiting NCT06233890 - The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
Completed NCT03882281 - Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia Phase 1
Recruiting NCT03459534 - A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs Phase 3
Completed NCT03885830 - Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
Active, not recruiting NCT04147533 - Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia Phase 2
Recruiting NCT03942094 - Nilotinib for First-line Newly Diagnosed CML-CP Patients Phase 3
Active, not recruiting NCT03933852 - Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose
Recruiting NCT05311943 - Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. Phase 3
Active, not recruiting NCT04160546 - Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) Phase 2
Recruiting NCT04677439 - Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure Phase 4
Active, not recruiting NCT03722420 - Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) Phase 3
Not yet recruiting NCT06163430 - CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia Phase 1
Completed NCT02977312 - Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan N/A